A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell

Published:2022-04 Issue: Volume:600 Page:94-100
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Zhi Lingtong,Yin Meichen,Su Xin,Zhang Zikang,Lu Hui,Li Mingfeng,Guo Changjiang,Niu Zhiyuan,Zhang Xuan,Zhu Wuling

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference28 articles.

1. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy;Rosenberg;Clin. Cancer Res.,2011

2. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia;Porter;N. Engl. J. Med.,2011

3. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N. Engl. J. Med.,2013

4. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer;Sakamoto;J. Transl. Med.,2015

5. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial;Arai;Cytotherapy,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?;Pharmacological Research;2024-05

2. Deciphering the molecular and clinical characteristics of TREM2, HCST, and TYROBP in cancer immunity: A comprehensive pan-cancer study;Heliyon;2024-03

3. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges;International Immunopharmacology;2022-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3